 Michael Blute
| Title | Lecturer on Surgery |
|---|
| Institution | Massachusetts General Hospital |
|---|
| Department | Surgery |
|---|
| Address | Massachusetts General Hospital
Surgery (Urology)
55 Fruit St
Boston MA 02114
|
|---|
|
|
|
 Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Hillelsohn JH, Duty B, Blute ML, Okhunov Z, Kashan M, Moldwin R, Ashley RN. Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol. 2012 Dec; 19(6):6573-7.
-
Blute ML, Okhunov Z, Moreira DM, George AK, Sunday S, Lobko II, Vira MA. Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int. 2013 Apr; 111(4 Pt B):E181-5.
-
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC. Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. Urology. 2012 Feb; 79(2):356-60.
-
Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep. 2012 Feb; 13(1):38-46.
-
Blute M. An interview with Michael Blute, MD. Interviewed by John Fitzpatrick. BJU Int. 2011 Nov; 108(9):1369-70.
-
Blute ML, George A, Herati A, Srinivasian A, Vira MA, Kavoussi LR, Richstone L. Intracorporeal neobladder reconstruction: pressure-flow urodyamic studies in cadaveric orthotopic neobladders. BJU Int. 2012 Feb; 109(3):434-6.
-
Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011 Dec; 60(6):1212-20.
-
Blute ML. Editorial comment. Urology. 2011 Sep; 78(3):619; author reply 619.
-
Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ. Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108(11):1762-8.
-
Umbreit EC, Shimko MS, Childs MA, Lohse CM, Cheville JC, Leibovich BC, Blute ML, Thompson RH. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2012 Jan; 109(2):190-4; discussion 194.
-
Boorjian SA, Blute ML. Editorial comment. Urology. 2011 Apr; 77(4):950-1.
-
Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011 Aug; 60(2):205-10.
-
Shuch B, Crispen PL, Leibovich BC, Larochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar; 107(5):724-8.
-
Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011 Apr 1; 17(7):1915-23.
-
Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011 May; 59(5):832-40.
-
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9.
-
Siddiqui SA, Boorjian SA, Blute ML, Rangel LJ, Bergstralh EJ, Karnes RJ, Frank I. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int. 2011 Feb; 107(3):383-8.
-
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011 Jul 1; 117(13):2873-82.
-
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1; 117(13):2883-91.
-
Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Long-term complications of conduit urinary diversion. J Urol. 2011 Feb; 185(2):562-7.
-
Breau RH, Crispen PL, Jenkins SM, Blute ML, Leibovich BC. Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol. 2011 Feb; 185(2):407-13.
-
Childs MA, Breau RH, Umbreit EC, Lohse CM, Cheville JC, Thompson RH, Blute ML, Leibovich BC. Metachronous renal tumours after surgical management of oncocytoma. BJU Int. 2011 Sep; 108(6):816-9.
-
Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ. Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5.
-
Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC. The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int. 2010 Dec; 106(11):1638-42.
-
Bruner B, Breau RH, Lohse CM, Leibovich BC, Blute ML. Renal nephrometry score is associated with urine leak after partial nephrectomy. BJU Int. 2011 Jul; 108(1):67-72.
-
Choo R, Quevedo F, Choo CS, Blute M. Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma? Can Urol Assoc J. 2010 Oct; 4(5):E137-40.
-
Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011 Jan; 59(1):18-23.
-
Tollefson MK, Blute ML. Editorial comment. Urology. 2010 Sep; 76(3):721-2; discussion 722.
-
Breau RH, Blute ML. Surgery for renal cell carcinoma metastases. Curr Opin Urol. 2010 Sep; 20(5):375-81.
-
Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9.
-
Atwell TD, Callstrom MR, Farrell MA, Schmit GD, Woodrum DA, Leibovich BC, Chow GK, Patterson DE, Blute ML, Charboneau JW. Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol. 2010 Oct; 184(4):1291-5.
-
Schmit GD, Atwell TD, Callstrom MR, Farrell MA, Leibovich BC, Patterson DE, Chow GK, Blute ML, Charboneau JW. Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients. J Endourol. 2010 Aug; 24(8):1255-62.
-
Umbreit EC, Crispen PL, Shimko MS, Farmer SA, Blute ML, Frank I. Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer. 2010 Jul 15; 116(14):3399-407.
-
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol. 2010 Sep; 58(3):340-5.
-
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Campbell SC, Blute ML. Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol. 2010 Sep; 58(3):331-6.
-
Crispen PL, Tabidian MR, Allmer C, Lohse CM, Breau RH, Blute ML, Cheville JC, Leibovich BC. Unclassified renal cell carcinoma: impact on survival following nephrectomy. Urology. 2010 Sep; 76(3):580-6.
-
Gettman MT, Blute ML. Radical prostatectomy: does surgical technique influence margin control? Urol Oncol. 2010 Mar-Apr; 28(2):219-25.
-
Blute ML. Editorial comment. J Urol. 2010 Apr; 183(4):1365.
-
Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010 Apr; 183(4):1309-15.
-
Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9.
-
Breau RH, Crispen PL, Jimenez RE, Lohse CM, Blute ML, Leibovich BC. Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol. 2010 Mar; 183(3):903-8.
-
Tollefson MK, Blute ML, Farmer SA, Frank I. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010 Jan; 183(1):81-6.
-
Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML. Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210(2):232-9.
-
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182(6):2708-14.
-
Crispen PL, Blute ML. Editorial comment. Urology. 2009 Nov; 74(5):1046; author reply 1046-7.
-
Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5.
-
Breau RH, Cheville JC, Lohse CM, Kwon ED, Blute ML. Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564. J Urol. 2009 Dec; 182(6):2979-80; author reply 2980-1.
-
Karnes RJ, Hatano T, Blute ML, Myers RP. Radical prostatectomy for high-risk prostate cancer. Jpn J Clin Oncol. 2010 Jan; 40(1):3-9.
-
Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol. 2009 Dec; 182(6):2601-6.
-
Tollefson MK, Krambeck AE, Leibovich BC, Blute ML, Chow GK. Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology. 2010 Jun; 75(6):1373-7.
-
Boorjian SA, Blute ML. Surgery for vena caval tumor extension in renal cancer. Curr Opin Urol. 2009 Sep; 19(5):473-7.
-
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct; 182(4):1271-9.
-
Blute ML. Editorial comment. Urology. 2009 Jul; 74(1):159; author reply 160.
-
Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7.
-
Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15; 115(10):2092-103.
-
Crispen PL, Blute ML. Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol. 2009 May; 55(5):1161-2.
-
Blute ML. No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer. J Urol. 2009 Jun; 181(6):2421-3.
-
Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009 Sep; 104(6):778-85.
-
Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80.
-
Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009 Jun; 55(6):1251-65.
-
Bruner B, Ashley R, Leibovich B, Blute M, LeRoy A. Case report: percutaneous catheter management of persistent urine leak due to iatrogenic infundibular stenosis after partial nephrectomy. J Endourol. 2009 Jan; 23(1):37-41.
-
Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009; 37:108-22.
-
Blute ML. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010 Jan; 57(1):110-1.
-
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104.
-
Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am. 2008 Nov; 35(4):673-8; viii.
-
Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML. Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008 Dec; 102(11):1551-5.
-
Crispen PL, Blute ML. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009 Feb; 55(2):307-9.
-
Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009 Feb; 55(2):261-70.
-
Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113(7):1544-51.
-
Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC. Outcomes following partial nephrectomy by tumor size. J Urol. 2008 Nov; 180(5):1912-7.
-
Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, Blute ML, Gettman MT. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int. 2009 Feb; 103(4):448-53.
-
Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol Oncol. 2008 Sep-Oct; 26(5):530-2.
-
Hakimian P, Blute M, Kashanian J, Chan S, Silver D, Shabsigh R. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int. 2008 Dec; 102(11):1509-14.
-
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14(16):5150-7.
-
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 1; 68(15):6054-8.
-
Kashanian J, Hakimian P, Blute M, Wong J, Khanna H, Wise G, Shabsigh R. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 2008 Dec; 102(11):1634-7.
-
Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML. Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. BJU Int. 2008 Nov; 102(9):1107-10.
-
Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. 2008 Jun; 179(6):2136-40; discussion 2140-1.
-
Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
-
Krambeck A, Iwaszko M, Leibovich B, Cheville J, Frank I, Blute M. Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery. BJU Int. 2008 Jun; 101(11):1375-9.
-
Ida CM, Wang X, Erickson-Johnson MR, Wenger DE, Blute ML, Nascimento AG, Oliveira AM. Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features. Am J Surg Pathol. 2008 Jun; 32(6):951-4.
-
Thompson RH, Cheville JC, Leibovich BC, Blute ML. Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882. J Urol. 2008 Jul; 180(1):409; author reply 409-10.
-
Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol. 2008 Jul; 180(1):99-103; discussion 103.
-
Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008 Jun; 5(6):329-39.
-
Blute ML. Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise? J Clin Oncol. 2008 May 10; 26(14):2248-9.
-
Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML. The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol. 2008 Oct; 54(4):855-63.
-
Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2008 May; 179(5 Suppl):S7-S11.
-
Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, Cheville JC, Blute ML. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. Urology. 2008 Jul; 72(1):148-52.
-
Nehra A, Kumar R, Ramakumar S, Myers RP, Blute ML, McKusick MA. Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s). J Urol. 2008 Jun; 179(6):2317-20.
-
Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008 Jun; 179(6):2146-51; discussion 2151.
-
Routh JC, Bacon DR, Leibovich BC, Zincke H, Blute ML, Frank I. How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery. BJU Int. 2008 Aug; 102(3):301-4.
-
Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol. 2008 Apr; 15(4):304-8.
-
Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008 May; 179(5):1830-7; discussion 1837.
-
Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179(4):1354-60; discussion 1360-1.
-
Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008 Apr; 179(4):1349-52; discussion 1352-3.
-
Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008 Apr; 71(4):713-7.
-
Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb; 179(2):468-71; discussion 472-3.
-
Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol. 2008 Feb; 179(2):474-7.
-
Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008 Feb; 71(2):278-82.
-
Sengupta S, Amling C, D'Amico AV, Blute ML. Prostate specific antigen kinetics in the management of prostate cancer. J Urol. 2008 Mar; 179(3):821-6.
-
Magera JS, Frank I, Lohse CM, Leibovich BC, Cheville JC, Blute ML. Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant. J Urol. 2008 Mar; 179(3):853-6.
-
Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
-
Crispen PL, Lohse CM, Blute ML. Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors
-
Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, Blute ML. The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. Urology. 2007 Dec; 70(6):1064-8.
-
Ashley RA, Inman BA, Routh JC, Mynderse LA, Gettman MT, Blute ML. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol. 2008 May; 53(5):976-81.
-
Webster WS, Thompson RH, Cheville JC, Lohse CM, Blute ML, Leibovich BC. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology. 2007 Nov; 70(5):900-4; discussion 904.
-
Ashley RA, Inman BA, Routh JC, Krambeck AE, Siddiqui SA, Mynderse LA, Gettman MT, Blute ML. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer. 2007 Oct 15; 110(8):1708-14.
-
Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304.
-
Granberg CF, Krambeck AE, Leibovich BC, Frank I, Lohse CM, Gettman MT, Blute ML, Chow GC. Potential underdetection of pT(3a) renal-cell carcinoma with laparoscopic morcellation. J Endourol. 2007 Oct; 21(10):1183-6.
-
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67(16):7893-900.
-
Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1.
-
Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Elliott DS, Blute ML. Imperative indications for conservative management of upper tract transitional cell carcinoma. J Urol. 2007 Sep; 178(3 Pt 1):792-6; discussion 796-7.
-
Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM, Kawashima A, Davis BJ, Blute ML. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology. 2007 Jul; 70(1):80-5.
-
Thompson RH, Blute ML, Krambeck AE, Lohse CM, Magera JS, Leibovich BC, Kwon ED, Frank I, Cheville JC. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol. 2007 Jul; 31(7):1089-93.
-
Gettman MT, Blute ML. Transvesical peritoneoscopy: initial clinical evaluation of the bladder as a portal for natural orifice translumenal endoscopic surgery. Mayo Clin Proc. 2007 Jul; 82(7):843-5.
-
Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
-
Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178(2):440-5; discussion 444.
-
Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, Kattan MW, Novick AC. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007 Jul; 178(1):41-6.
-
Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):969-78.
-
Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol. 2007 May; 177(5):1721-6.
-
Boorjian SA, Sengupta S, Blute ML. Renal cell carcinoma: vena caval involvement. BJU Int. 2007 May; 99(5 Pt B):1239-44.
-
Thompson RH, Blute ML. At what point does warm ischemia cause permanent renal damage during partial nephrectomy? Eur Urol. 2007 Oct; 52(4):961-3.
-
Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
-
Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13(7):2075-81.
-
Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res. 2007 Apr 1; 67(7):2944-50.
-
Blute ML. Nephron-sparing surgery: the 'gold standard' treatment for small renal cortical tumors. Nat Clin Pract Urol. 2007 Jun; 4(6):300-1.
-
Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1749-56.
-
Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1757-61.
-
Atwell TD, Farrell MA, Callstrom MR, Charboneau JW, Leibovich BC, Patterson DE, Chow GK, Blute ML. Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience. Radiology. 2007 Apr; 243(1):276-83.
-
Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol. 2007 Feb; 177(2):477-80.
-
Thompson RH, Frank I, Lohse CM, Saad IR, Fergany A, Zincke H, Leibovich BC, Blute ML, Novick AC. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol. 2007 Feb; 177(2):471-6.
-
Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, Blute ML. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol. 2007 Jan; 177(1):59-62.
-
Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol. 2007 Mar; 38(3):453-61.
-
Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol. 2006 Nov; 176(5):1990-5; discussion 1995.
-
Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006 Nov; 176(5):1978-82; discussion 1982-3.
-
Leibovich BC, Blute ML. Surgical management of renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):552-62.
-
Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006 Oct; 68(4):741-6.
-
Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8.
-
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006 Sep; 176(3):900-3; discussion 903-4.
-
Humphreys MR, Ereth MH, Sebo TJ, Slezak JM, Dong Y, Blute ML, Gettman MT. Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits. BJU Int. 2006 Sep; 98(3):674-9.
-
Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol. 2006 Sep; 176(3):1118-21.
-
Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006 Aug 15; 107(4):712-20.
-
Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 1; 107(3):521-9.
-
Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006 Aug; 176(2):559-63.
-
Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006 Jul 1; 107(1):46-53.
-
Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 1; 107(1):37-45.
-
Sengupta S, Cheville JC, Lohse CM, Zincke H, Myers RP, Riehle DL, Pankratz VS, Blute ML, Sebo TJ. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. Urology. 2006 Jul; 68(1):94-8.
-
Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther. 2006 Jul-Aug; 13(4):291-7.
-
Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006 Jul 5; 103(27):10391-6.
-
Sengupta S, Slezak JM, Blute ML, Leibovich BC, Sebo TJ, Myers RP, Cheville JC, Bergstralh EJ, Zincke H. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
-
Gettman MT, Blute ML. Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost. Curr Urol Rep. 2006 May; 7(3):193-9.
-
Sengupta S, Blute ML, Bagniewski SM, Myers RP, Bergstralh EJ, Leibovich BC, Zincke H. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol. 2006 May; 175(5):1684-90; discussion 1690.
-
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66(7):3381-5.
-
Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol. 2006 Mar; 175(3 Pt 1):952-7.
-
Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology. 2006 Mar; 67(3 Suppl 1):48-54; discussion 54-5.
-
Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS. The use of urine-based biomarkers in bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):62-4.
-
Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006 Feb; 175(2):547-51.
-
Sengupta S, Slezak JM, Blute ML, Bergstralh EJ. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology. 2006 Feb; 67(2):408-9.
-
Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006 Jan 15; 106(2):304-12.
-
Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol. 2006 Jan; 175(1):53-6.
-
Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
-
Sengupta S, Zincke H, Blute ML. Re: The accuracy of 250 fine needle biopsies of renal tumors. J Urol. 2005 Dec; 174(6):2422; author reply 2422.
-
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005 Nov 15; 104(10):2084-91.
-
Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):10-4.
-
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005 Nov; 174(5):1759-63; discussion 1763.
-
Tollefson MK, Kawashima A, Blute ML. In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney. Urology. 2005 Oct; 66(4):882.
-
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005 Oct; 174(4 Pt 1):1218-21.
-
Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML. Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol. 2005 Sep; 174(3):855-8.
-
Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005 Aug 1; 104(3):511-20.
-
Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005 Jul 15; 11(14):5128-39.
-
Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2005 Jul; 174(1):107-10; discussion 110-1.
-
Sengupta S, Zincke H, Leibovich BC, Blute ML. Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series. BJU Int. 2005 Jul; 96(1):54-7.
-
Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005 Jul 1; 104(1):53-60.
-
Sengupta S, Leibovich BC, Blute ML, Zincke H. Surgery for metastatic renal cell cancer. World J Urol. 2005 Jul; 23(3):155-60.
-
Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173(6):1893-6.
-
Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005 Jun; 173(6):1889-92.
-
Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV, Zincke H, Blute ML. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol. 2005 Jun; 173(6):1953-7.
-
Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology. 2005 Jun; 65(6):1090-5.
-
DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
-
Krambeck AE, Miller DV, Blute ML. Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery. Urology. 2005 Apr; 65(4):798.
-
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
-
Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005 Apr; 173(4):1156-60.
-
Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005 Mar; 173(3):918-21.
-
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, Thompson RH, Blute ML. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005 Mar; 173(3):716-9.
-
Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol. 2005 Feb; 173(2):391-4.
-
Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, Zincke H. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005 Feb; 173(2):380-4.
-
Gillett MD, Gettman MT, Zincke H, Blute ML. Tissue ablation technologies for localized prostate cancer. Mayo Clin Proc. 2004 Dec; 79(12):1547-55.
-
Dimashkieh HH, Jevremovic D, Blute ML, Lager DJ. Pathologic quiz case: a 56-year-old man with bilateral renal masses. Bilateral renal oncocytosis. Arch Pathol Lab Med. 2004 Dec; 128(12):e177-8.
-
Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8.
-
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17174-9.
-
Gettman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R. Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology. 2004 Nov; 64(5):914-8.
-
Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004 Oct 15; 101(8):1803-8.
-
Schaid DJ, Guenther JC, Christensen GB, Hebbring S, Rosenow C, Hilker CA, McDonnell SK, Cunningham JM, Slager SL, Blute ML, Thibodeau SN. Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet. 2004 Dec; 75(6):948-65.
-
Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
-
Cheville JC, Frank I, Leibovich BC, Lohse CM, Blute ML. Re: Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol. 2004 Sep; 172(3):1196; author reply 1196.
-
Humphreys MR, Gettman MT, Chow GK, Zincke H, Blute ML. Minimally invasive radical prostatectomy. Mayo Clin Proc. 2004 Sep; 79(9):1169-80.
-
Dimarco DS, Lohse CM, Zincke H, Cheville JC, Blute ML. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology. 2004 Sep; 64(3):462-7.
-
Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004 Aug; 172(2):465-9.
-
Thompson JL, Blute ML. Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy. Urology. 2004 Aug; 64(2):376-7.
-
Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004 Jul; 94(1):33-41.
-
Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA. 2004 Jun 16; 291(23):2817; author reply 2817-8.
-
Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer. 2004 Jun 15; 100(12):2577-82.
-
Brown DR, Hofer RE, Patterson DE, Fronapfel PJ, Maxson PM, Narr BJ, Eisenach JH, Blute ML, Schroeder DR, Warner DO. Intrathecal anesthesia and recovery from radical prostatectomy: a prospective, randomized, controlled trial. Anesthesiology. 2004 Apr; 100(4):926-34.
-
Young CY, Jatoi A, Ward JF, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem. 2004 Apr; 11(7):909-23.
-
Leung N, Ytterberg SR, Blute ML, Lager DJ, Specks U, Fervenza FC. Wegener's granulomatosis presenting as multiple bilateral renal masses. Nephrol Dial Transplant. 2004 Apr; 19(4):984-7.
-
Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR, Blute ML, Roehrborn CG, Partin AW. Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years. Urology. 2004 Apr; 63(4):716-21.
-
Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004 Apr; 28(4):435-41.
-
Frank I, Blute ML. Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress. Mayo Clin Proc. 2004 Mar; 79(3):307-8.
-
Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004 Mar; 171(3):1066-70.
-
Blute ML, Bergstralh E. Re: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the Search database. J Urol. 2004 Feb; 171(2 Pt 1):808; author reply 808-9.
-
Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol. 2004 Jan-Feb; 22(1):40-7.
-
Cunningham JM, McDonnell SK, Marks A, Hebbring S, Anderson SA, Peterson BJ, Slager S, French A, Blute ML, Schaid DJ, Thibodeau SN. Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate. 2003 Dec 1; 57(4):335-46.
-
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, Zincke H. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003 Dec; 170(6 Pt 1):2225-32.
-
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003 Dec; 170(6 Pt 1):2217-20.
-
Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
-
Farrell MA, Charboneau JW, Callstrom MR, Reading CC, Engen DE, Blute ML. Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2003 Nov; 181(5):1315-7.
-
DiMarco DS, Blute ML, Zincke H, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Sebo TJ. Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less. Urol Oncol. 2003 Nov-Dec; 21(6):439-46.
-
Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology. 2003 Oct; 62(4):641-6.
-
Wang L, McDonnell SK, Cunningham JM, Hebbring S, Jacobsen SJ, Cerhan JR, Slager SL, Blute ML, Schaid DJ, Thibodeau SN. No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet. 2003 Oct; 35(2):128-9.
-
Blute M, Thibault GP, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence. J Urol. 2003 Sep; 170(3):760-3.
-
Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol. 2003 Aug; 170(2 Pt 1):420-4.
-
Chow GK, Patterson DE, Blute ML, Segura JW. Ureteroscopy: effect of technology and technique on clinical practice. J Urol. 2003 Jul; 170(1):99-102.
-
Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML. Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int. 2003 Jun; 91(9):775-9.
-
Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer. 2003 May 15; 97(10):2425-31.
-
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003 May; 27(5):612-24.
-
Ward JF, Blute ML. Chemoprevention of prostate cancer. Expert Rev Anticancer Ther. 2003 Apr; 3(2):203-14.
-
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Apr 1; 97(7):1663-71.
-
Blute ML, Itano NB, Cheville JC, Weaver AL, Lohse CM, Zincke H. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol. 2003 Apr; 169(4):1276-81.
-
Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003 Apr; 169(4):1282-6.
-
Gettman MT, Blute ML, Peschel R, Bartsch G. Current status of robotics in urologic laparoscopy. Eur Urol. 2003 Feb; 43(2):106-12.
-
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003 Feb; 72(2):270-80.
-
Dechet CB, Zincke H, Sebo TJ, King BF, LeRoy AJ, Farrow GM, Blute ML. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003 Jan; 169(1):71-4.
-
Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol. 2002 Dec; 118(6):877-86.
-
Nuttall GA, Cragun MD, Hill DL, Morris TJ, Decker PA, Blute ML, Patterson DE, Warner DO. Radical retropubic prostatectomy and blood transfusion. Mayo Clin Proc. 2002 Dec; 77(12):1301-5.
-
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002 Dec; 168(6):2395-400.
-
Kausik SJ, Blute ML, Sebo TJ, Leibovich BC, Bergstralh EJ, Slezak J, Zincke H. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002 Sep 15; 95(6):1215-9.
-
Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol. 2002 Sep; 168(3):1204-11.
-
Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002 Sep 1; 95(5):1028-36.
-
Jacobsen SJ, Thibodeau SN, McDonnell SK, Peterson BJ, Bergstralh EJ, Schaid DJ, Blute ML. Lack of referral bias in genetic studies of prostate cancer. Epidemiology. 2002 Sep; 13(5):612-3.
-
O'Leary MP, Baum NH, Blizzard R, Blute ML, Cooper TP, Dineen MK, Fenninger RB, Gee WF, Gormley EA, Ignatoff JM, Nachtsheim DA, Painter MR, Thomas R, Wei JT. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002 Aug; 168(2):649-52.
-
Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 1; 95(3):513-9.
-
Gettman MT, Blute ML. Update on pathologic staging of renal cell carcinoma. Urology. 2002 Aug; 60(2):209-17.
-
Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002 Aug; 168(2):525-9.
-
Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, Blute ML. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol. 2002 Aug; 168(2):454-9.
-
Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002 Jul; 168(1):56-60.
-
Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet. 2002 Jul; 71(1):116-23.
-
Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May; 167(5):2001-6.
-
Cheville JC, Zincke H, Lohse CM, Sebo TJ, Riehle D, Weaver AL, Blute ML. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer. 2002 Apr 15; 94(8):2180-4.
-
Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol. 2002 Apr; 26(4):431-9.
-
Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002 Apr; 59(4):532-7.
-
Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002 Feb; 14 Suppl 1:S38-42.
-
Gettman MT, Blute ML. Surgical management of renal cell carcinoma invading the vena cava. Curr Urol Rep. 2002 Feb; 3(1):37-43.
-
Manyak MJ, Ackerman SJ, Blute ML, Rein AL, Buesterien K, Sullivan EM, Tanio CP, Strauss MJ. Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy. J Endourol. 2002 Feb; 16(1):51-6.
-
Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, Zincke H. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996. J Urol. 2002 Feb; 167(2 Pt 2):884-9; discussion 889-90.
-
Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan; 167(1):117-22.
-
Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol. 2001 Dec; 166(6):2208-15.
-
Blute ML, Larson T. Minimally invasive therapies for benign prostatic hyperplasia. Urology. 2001 Dec; 58(6 Suppl 1):33-40; discussion 40-1.
-
Blute ML, Jacobsen SJ, Kaplan SA, Lowe FC, O'Leary MP, Steers WD, Roehrborn CG. Introduction. Urology. 2001 Dec; 58(6 Suppl 1):1-4.
-
Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001 Nov; 166(5):1692-7.
-
Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001 Sep 1; 61(17):6494-9.
-
Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival. J Urol. 2001 Aug; 166(2):453-6.
-
Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology. 2001 Aug; 58(2):174-8.
-
Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001 Jun 15; 91(12):2302-14.
-
Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
-
Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
-
Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer. 2001 Jun 1; 91(11):2196-204.
-
Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001 Apr; 165(4):1146-51.
-
Alberts SR, Blute ML. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology. 2001 Apr; 57(4 Suppl 1):188-90.
-
Elliott DS, Lightner DJ, Blute ML. Medical management of overactive bladder. Mayo Clin Proc. 2001 Apr; 76(4):353-5.
-
Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer. 2001 Jan 15; 91(2):354-61.
-
Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001 Jan 1; 91(1):66-73.
-
Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001 Jan; 165(1):119-25.
-
Blute M, Ackerman SJ, Rein AL, Beusterien K, Sullivan EM, Tanio CP, Strauss MJ, Manyak MJ. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results. Urology. 2000 Dec 20; 56(6):981-7.
-
Ackerman SJ, Rein AL, Blute M, Beusterien K, Sullivan EM, Tanio CP, Manyak MJ, Strauss MJ. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology. 2000 Dec 20; 56(6):972-80.
-
Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000 Dec; 75(12):1236-42.
-
Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164(5):1591-5.
-
Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000 Nov 1; 56(5):726-9.
-
O'Leary MP, Gee WF, Holtgrewe HL, Blute ML, Cooper TP, Miles BJ, Nellans RE, Thomas R, Painter MR, Meyer JJ, Naslund MJ, Gormley EA, Blizzard R, Fenninger RB. 1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol. 2000 Oct; 164(4):1311-6.
-
Blute ML, Amling CL, Bryant SC, Zincke H. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease. Mayo Clin Proc. 2000 Oct; 75(10):1020-6.
-
Karnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML. Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus. J Urol. 2000 Sep; 164(3 Pt 1):772.
-
Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000 Aug; 164(2):322-5.
-
Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
-
Knight MK, Blute ML. Incidental discovery of pelvic leiomyosarcoma at radical prostatectomy. J Urol. 2000 Jun; 163(6):1866.
-
Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000 May; 6(5):1896-9.
-
Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000 Apr; 163(4):1178-82.
-
Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar; 163(3):845-50.
-
Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK, Peterson BJ, Wang ZY, Carpten JD, Roberts SG, Tester DJ, Blute ML, Trent JM, Thibodeau SN. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet. 2000 Feb; 66(2):539-46.
-
O'Leary MP, Gee WF, Holtgrewe HL, Blute ML, Cooper TP, Meyer JJ, Miles BJ, Naslund MJ, Nellans RE, Thomas R, Painter MR, Blizzard R, Fenninger RB. 1998 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of ureteral stones and impact of managed care. J Urol. 1999 Nov; 162(5):1702-4.
-
Blute ML, Zincke H. Re: Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Oct; 162(4):1391-2.
-
Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999 Oct; 5(10):2820-3.
-
Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. 1999 Oct; 162(4):1282-4; discussion 1284-5.
-
Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
-
Ghavamian R, Blute ML, Bergstralh EJ, Slezak J, Zincke H. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
-
Dechet CB, Bostwick DG, Blute ML, Bryant SC, Zincke H. Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol. 1999 Jul; 162(1):40-2.
-
Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999 Apr; 161(4):1223-7; discussion 1227-8.
-
Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG. Predictors of cancer progression in T1a prostate adenocarcinoma. Cancer. 1999 Mar 15; 85(6):1300-4.
-
Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar; 161(3):857-62; discussion 862-3.
-
Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999 Feb; 161(2):388-94.
-
Corica FA, Iczkowski KA, Cheng L, Zincke H, Blute ML, Wendel A, Sebo TJ, Neumann R, Bostwick DG. Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. J Urol. 1999 Feb; 161(2):408-11.
-
Seelig MH, Oldenburg WA, Klingler PJ, Blute ML, Pairolero PC. Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. J Vasc Surg. 1999 Feb; 29(2):377-81.
-
Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998 Dec; 22(12):1491-500.
-
Djavan B, Larson TR, Blute ML, Marberger M. Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Urology. 1998 Dec; 52(6):935-47.
-
Gee WF, Holtgrewe HL, Blute ML, Miles BJ, Naslund MJ, Nellans RE, O'Leary MP, Thomas R, Painter MR, Meyer JJ, Rohner TJ, Cooper TP, Blizzard R, Fenninger RB, Emmons L. 1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol. 1998 Nov; 160(5):1804-7.
-
Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998 Oct; 20(2):175-9.
-
Gburek BM, Lieber MM, Blute ML. Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol. 1998 Sep; 160(3 Pt 1):721-3.
-
Cheng L, Neumann RM, Blute ML, Zincke H, Bostwick DG. Long-term follow-up of untreated stage T1a prostate cancer. J Natl Cancer Inst. 1998 Jul 15; 90(14):1105-7.
-
Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet. 1998 Jun; 62(6):1425-38.
-
Blute ML, Gburek BM. Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience. Mayo Clin Proc. 1998 Jun; 73(6):501-7.
-
Larson TR, Blute ML, Tri JL, Whitlock SV. Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia. Urology. 1998 Jun; 51(6):908-15.
-
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998 Jun 1; 82(11):2256-61.
-
Blute ML, Larson TR, Hanson KA, King BF. Current status of transurethral thermotherapy at the Mayo Clinic. Mayo Clin Proc. 1998 Jun; 73(6):597-602.
-
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998 May; 159(5):1497-503.
-
Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998 May; 73(5):401-6.
-
Larson TR, Blute ML, Bruskewitz RC, Mayer RD, Ugarte RR, Utz WJ. A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology. 1998 May; 51(5):731-42.
-
Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, Zincke H. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer. 1998 Mar 1; 82(5):902-8.
-
Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998 Feb; 159(2):357-64.
-
Francisca E, Blute M, de la Rosette J. Quality-of-life assessment in patients treated with lower-energy thermotherapy: Prostasoft 2.0. World J Urol. 1998; 16(2):148-52.
-
de la Rosette JJ, Blute ML, Desgrandchamp F. Transurethral thermotherapy using the Prostatron device. World J Urol. 1998; 16(2):89-95.
-
Brown JA, Segura JW, Blute ML. A giant left renal cyst presenting as obesity: a unique presentation. Arch Esp Urol. 1998 Jan-Feb; 51(1):105-7.
-
Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology. 1998 Jan; 51(1):79-85.
-
Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP, Zincke H. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol. 1997 Nov; 15(4):215-21.
-
Amling CL, Blute ML, Bergstralh EJ, Slezak JM, Martin SK, Zincke H. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):222-9.
-
Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997 Nov; 50(5):733-9.
-
Hanash KA, Aquilina JW, Barrett DM, Blute ML, Cockett AT, Corica FA, Hillman GG, Zbar B, Zhuang Z. Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs--Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997 Sep 1; 80(5):999-1001.
-
Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997 Sep 1; 80(5):987-9.
-
Blute ML. Transurethral microwave thermotherapy: minimally invasive therapy for benign prostatic hyperplasia. Urology. 1997 Aug; 50(2):163-6.
-
Harmon WJ, Sershon PD, Blute ML, Patterson DE, Segura JW. Ureteroscopy: current practice and long-term complications. J Urol. 1997 Jan; 157(1):28-32.
-
vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997 Jan; 49(1):65-70.
-
Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy v sham treatment: double-blind randomized study. J Endourol. 1996 Dec; 10(6):565-73.
-
Blute ML. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 1996 Nov; 154(5):1580-1.
-
Lerner SE, Blute ML, Richardson RL, Zincke H. Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clin Proc. 1996 Oct; 71(10):945-50.
-
Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Oct 1; 36(3):585-91.
-
Lerner SE, Jacobsen SJ, Lilja H, Bergstralh EJ, Ransom J, Klee GG, Piironen T, Blute ML, Lieber MM, Zincke H, Pettersson K, Peterson D, Oesterling JE. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology. 1996 Aug; 48(2):240-8.
-
Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodrigue R, Henson DE, Mostofi FK, Seiffert J, Wojno K, Zincke H. Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
-
Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996 Jul; 156(1):137-43.
-
Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
-
Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, Zincke H. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996 Jun; 155(6):1868-73.
-
Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996 Jun; 47(6):819-25.
-
Kletscher BA, Qian J, Bostwick DG, Blute ML, Zincke H. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996 Jun; 155(6):1844-6.
-
Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol. 1996 May; 14(2 Suppl 2):12-20; discussion 21.
-
Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol. 1996 Mar; 155(3):821-6.
-
Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995 Oct; 154(4):1447-52.
-
Blute ML. Refining the early detection and staging of prostate cancer. J Urol. 1995 Oct; 154(4):1401-2.
-
Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol. 1995 Sep; 154(3):1103-9.
-
Lerner SE, Mann BS, Blute ML, Richardson RL, Zincke H. Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. Mayo Clin Proc. 1995 Sep; 70(9):821-8.
-
Lerner SE, Blute ML, Lieber MM, Zincke H. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995 May; 9(5):379-82; discussion 382, 385-6, 389.
-
Hanson K, Blute ML. Endourologic diagnosis and conservative management of upper tract urothelial cancer. Urol Nurs. 1994 Dec; 14(4):159-63.
-
Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994 Nov; 152(5 Pt 2):1850-7.
-
Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol. 1994 Nov; 12(11):2254-63.
-
Blute ML. Microwave thermotherapy for the treatment of benign prostatic hyperplasia. Semin Urol. 1994 Aug; 12(3):181-92.
-
Zincke H, Blute ML. Renal tumors. J Urol. 1994 Jul; 152(1):43-4.
-
Torres VE, King BF, Holley KE, Blute ML, Gomez MR. The kidney in the tuberous sclerosis complex. Adv Nephrol Necker Hosp. 1994; 23:43-70.
-
Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Lynch JH, Regan JB, Sankey NE. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol. 1993 Nov; 150(5 Pt 2):1591-6.
-
Guthman DA, Wilson TM, Blute ML, Bergstralh EJ, Zincke H, Oesterling JE. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology. 1993 Aug; 42(2):150-4.
-
Kerr LA, Blute ML, Ryu JH, Swensen SJ, Malek RS. Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis? Urology. 1993 May; 41(5):440-4.
-
Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology. 1993 Jan; 41(1):3-8.
-
Allaire PH, Messick JM, Oesterling JE, Byer DE, Myers RP, Lieber MM, Chantigian RC, Welna JO, Patterson DE, Blute ML, et al. A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. Mayo Clin Proc. 1992 Nov; 67(11):1031-41.
-
Blute ML, Tomera KM, Hellerstein DK, Atkinson EJ, Patterson DE, Segura JW. Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience. Mayo Clin Proc. 1992 May; 67(5):417-21.
-
Kallman DA, King BF, Hattery RR, Charboneau JW, Ehman RL, Guthman DA, Blute ML. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr. 1992 Mar-Apr; 16(2):240-7.
-
Blute ML, Lewis RW. Local microwave hyperthermia as a treatment alternative for benign prostatic hyperplasia. J Androl. 1991 Nov-Dec; 12(6):429-34.
-
Zincke H, Blute ML, Fallen MJ, Farrow GM. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. 1991 Oct; 146(4):1053-8.
-
Kerley SW, Blute ML, Keeney GL. Multifocal malignant melanoma arising in vesicovaginal melanosis. Arch Pathol Lab Med. 1991 Sep; 115(9):950-2.
-
Montgomery BT, Kelalis PP, Blute ML, Bergstralh EJ, Beckwith JB, Norkool P, Green DM, D'Angio GJ. Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study. J Urol. 1991 Aug; 146(2 ( Pt 2)):514-8.
-
Strawbridge LR, Blute ML, James EM, Gillespie DJ. Intraoperative ultrasonographically guided biopsy in testicular sarcoidosis: a case report. J Urol. 1990 Jun; 143(6):1229-31.
-
Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, Therneau TM, Lieber MM. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg. 1990 Mar; 125(3):327-31.
-
Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989 Nov; 142(5):1262-5.
-
Blute ML, Segura JW, Patterson DE, Benson RC, Zincke H. Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol. 1989 Jun; 141(6):1298-301.
-
Blute ML, Engen DE, Travis WD, Kvols LK. Primary signet ring cell adenocarcinoma of the bladder. J Urol. 1989 Jan; 141(1):17-21.
-
Blute ML, Tsushima K, Farrow GM, Therneau TM, Lieber MM. Transitional cell carcinoma of the renal pelvis: nuclear deoxyribonucleic acid ploidy studied by flow cytometry. J Urol. 1988 Nov; 140(5):944-9.
-
Blute ML, Segura JW, Patterson DE. Ureteroscopy. J Urol. 1988 Mar; 139(3):510-2.
-
Blute ML, Malek RS, Segura JW. Angiomyolipoma: clinical metamorphosis and concepts for management. J Urol. 1988 Jan; 139(1):20-4.
-
Blute ML, Kelalis PP, Offord KP, Breslow N, Beckwith JB, D'Angio GJ. Bilateral Wilms tumor. J Urol. 1987 Oct; 138(4 Pt 2):968-73.
-
Blute ML, Zincke H, Farrow GM. Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol. 1986 Oct; 136(4):840-3.
-
Blute ML, Templeton AC. Unilateral renal cortical necrosis. Br J Urol. 1985 Apr; 57(2):243-4.
This graph shows the total number of publications by year.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
|
Blute's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|